Scancell Holdings has announced that its ImmunoBody vaccine, SCIB2, is to be administered using a new nanoparticle formulation in a planned Phase I/II clinical trial.
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area.